Georgios Tsermoulas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgios Tsermoulas has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Susan Patricia Mollan
Metabolism and Systems Science, School of Medical Sciences, University of Birmingham, Birmingham, UK
10 shared publications - Alexandra Jean Sinclair
Metabolism and Systems Science, University of Birmingham, Birmingham, UK
9 shared publications - Andreas Yiangou
Metabolism and Systems Science, School of Medical Sciences, College of Medicine and Health, University of Birmingham , Birmingham B15 2TT
6 shared publications - Mark Thaller
Metabolism and Systems Science, School of Medical Sciences, University of Birmingham, Birmingham, UK
6 shared publications - James L. Mitchell
Department of Biomedical Sciences, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, United Kingdom
5 shared publications - Hannah S. Lyons
Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, United Kingdom
4 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1965112
Intracranial pulsatile pressure gradient: a hypothesis and the potential role of dual intracranial pressure monitoring
Intracranial pressure (ICP) monitoring is widely used in neurosurgical practice and the two key ICP variables, mean pressure and pulse amplitude, provide important information about intracranial compliance and cerebrospinal fluid dynamics. Mean ICP is assumed to be uniformly distributed and monitoring at a single intracranial location is considered representative of global ICP, but whether pulse amplitude is spatially uniform within the intracranial cavity remains uncertain. This article proposes the hypothesis that ICP waves undergo spatial attenuation within the skull resulting in an intracranial pulsatile pressure gradient. The hypothesis is supported by physiological principles of wave propagation and by evidence demonstrating attenuation of pressure waves along the craniospinal axis, although intracranial attenuation has not yet been experimentally demonstrated. This manuscript proposes that this hypothesis could be investigated using synchronous ICP measurements at two intracranial sites separated by a defined distance. It also describes the concept of a dual-sensor intracranial catheter, incorporating deep and superficial pressure sensors, that could provide simultaneous measurements and quantify the hypothetical spatial attenuation. Demonstrating an intracranial pulsatile pressure gradient could provide new insights into intracranial hydrodynamics and the interpretation of ICP pulsatility, with potential implications for neurosurgical conditions including traumatic brain injury, normal pressure hydrocephalus, idiopathic intracranial hypertension, and Chiari malformation.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1965112
Open AccessIntracranial pulsatile pressure gradient: a hypothesis and the potential role of dual intracranial pressure monitoring
Intracranial pressure (ICP) monitoring is widely used in neurosurgical practice and the two key ICP variables, mean pressure and pulse amplitude, provide important information about intracranial compliance and cerebrospinal fluid dynamics. Mean ICP is assumed to be uniformly distributed and monitoring at a single intracranial location is considered representative of global ICP, but whether pulse amplitude is spatially uniform within the intracranial cavity remains uncertain. This article proposes the hypothesis that ICP waves undergo spatial attenuation within the skull resulting in an intracranial pulsatile pressure gradient. The hypothesis is supported by physiological principles of wave propagation and by evidence demonstrating attenuation of pressure waves along the craniospinal axis, although intracranial attenuation has not yet been experimentally demonstrated. This manuscript proposes that this hypothesis could be investigated using synchronous ICP measurements at two intracranial sites separated by a defined distance. It also describes the concept of a dual-sensor intracranial catheter, incorporating deep and superficial pressure sensors, that could provide simultaneous measurements and quantify the hypothetical spatial attenuation. Demonstrating an intracranial pulsatile pressure gradient could provide new insights into intracranial hydrodynamics and the interpretation of ICP pulsatility, with potential implications for neurosurgical conditions including traumatic brain injury, normal pressure hydrocephalus, idiopathic intracranial hypertension, and Chiari malformation.
- Open Access
- 22 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2633-2640
Optical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension
Background: Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could be easily facilitated. Methods: People living with idiopathic intracranial hypertension (IIH) underwent non-dilated same-day OCT imaging performed on Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and Cirrus 6000 OCT (Carl Zeiss Meditec, Dublin, CA). Comparable measurements were collected (retinal nerve fibre layer (RNFL), maximum height of the optic nerve head and macular ganglion cell layer assessment). Bland-Altman plots were constructed, intraclass correlation coefficient (ICC) and Pearson correlation coefficient were calculated. Results: Ninety-seven people with a definite diagnosis of IIH were included: 95% were women with a mean age of 31 years. Mean global RNFL thickness was 117.4μm (SD 41.6) on the Spectralis platform and 122.5μm (SD 53.8) on the Cirrus platform. There was excellent agreement between the devices for RNFL thickness measurements (ICC = 0.922), although the Bland-Altman plot revealed increasing discrepancy at higher RNFL thicknesses. Maximum disc height displayed good agreement (ICC = 0.882) between devices. There was a very strong positive correlation between Spectralis GCL volume and Cirrus GC-IPL thickness(r = 0.911). Conclusions: This OCT imaging dataset spanning a range of papilloedema severity in people with a definite diagnosis of IIH showed good relative agreement of RNFL measurements between Spectralis and Cirrus devices at RNFL thicknesses close to normal, but greater variance with more severe papilloedema. RNFL measurements from the two devices cannot be used interchangeably. Macular GCL assessments showed a strong positive linear correlation.
- 22 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2633-2640
Open AccessOptical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension
Background: Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could be easily facilitated. Methods: People living with idiopathic intracranial hypertension (IIH) underwent non-dilated same-day OCT imaging performed on Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and Cirrus 6000 OCT (Carl Zeiss Meditec, Dublin, CA). Comparable measurements were collected (retinal nerve fibre layer (RNFL), maximum height of the optic nerve head and macular ganglion cell layer assessment). Bland-Altman plots were constructed, intraclass correlation coefficient (ICC) and Pearson correlation coefficient were calculated. Results: Ninety-seven people with a definite diagnosis of IIH were included: 95% were women with a mean age of 31 years. Mean global RNFL thickness was 117.4μm (SD 41.6) on the Spectralis platform and 122.5μm (SD 53.8) on the Cirrus platform. There was excellent agreement between the devices for RNFL thickness measurements (ICC = 0.922), although the Bland-Altman plot revealed increasing discrepancy at higher RNFL thicknesses. Maximum disc height displayed good agreement (ICC = 0.882) between devices. There was a very strong positive correlation between Spectralis GCL volume and Cirrus GC-IPL thickness(r = 0.911). Conclusions: This OCT imaging dataset spanning a range of papilloedema severity in people with a definite diagnosis of IIH showed good relative agreement of RNFL measurements between Spectralis and Cirrus devices at RNFL thicknesses close to normal, but greater variance with more severe papilloedema. RNFL measurements from the two devices cannot be used interchangeably. Macular GCL assessments showed a strong positive linear correlation.
- Open Access
- 13 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (2)
Ten-year spontaneous intracranial hypotension with acquired tonsillar descent and syringomyelia from a T3–4 ventral dural defect: importance of digital subtraction myelography localization and role of direct repair. Illustrative case
BACKGROUND: Spontaneous intracranial hypotension (SIH) is an underrecognized yet increasingly diagnosed cause of orthostatic headaches. Reduction of intracranial CSF volume and pressure produces characteristic imaging findings such as diffuse pachymeningeal enhancement and cerebellar tonsillar descent, mimicking a Chiari malformation type I. Distinguishing SIH from other causes of hindbrain herniation is critical for prompt recognition and targeted treatment to resolve symptoms and radiological abnormalities. OBSERVATIONS: A 55-year-old male patient presented with a history of persisting postural headaches, back pain, and sensory loss. MRI of the spine demonstrated a subtle ventral epidural fluid collection extending along the cervical and thoracic spine. Intraoperative digital subtraction myelography confirmed a CSF leak site at the T3–4 level due to a dural defect. Under the same anesthetic, a posterior T3–4 laminectomy and intradural repair of the ventral dural defect were performed. The patient recovered with complete resolution of symptoms and no neurological deficits or weakness. Postoperative MRI showed resolution. LESSONS: Identifying a pathological defect can be challenging in SIH, especially in chronic cases that mimic Chiari malformation type I due to tonsillar decent. The authors illustrate the clinical, radiological, and surgical framework utilized at their institution for managing a chronic SIH case due to a ventral dural defect. https://thejns.org/doi/10.3171/CASE26369
- 13 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (2)
Open AccessTen-year spontaneous intracranial hypotension with acquired tonsillar descent and syringomyelia from a T3–4 ventral dural defect: importance of digital subtraction myelography localization and role of direct repair. Illustrative case
BACKGROUND: Spontaneous intracranial hypotension (SIH) is an underrecognized yet increasingly diagnosed cause of orthostatic headaches. Reduction of intracranial CSF volume and pressure produces characteristic imaging findings such as diffuse pachymeningeal enhancement and cerebellar tonsillar descent, mimicking a Chiari malformation type I. Distinguishing SIH from other causes of hindbrain herniation is critical for prompt recognition and targeted treatment to resolve symptoms and radiological abnormalities. OBSERVATIONS: A 55-year-old male patient presented with a history of persisting postural headaches, back pain, and sensory loss. MRI of the spine demonstrated a subtle ventral epidural fluid collection extending along the cervical and thoracic spine. Intraoperative digital subtraction myelography confirmed a CSF leak site at the T3–4 level due to a dural defect. Under the same anesthetic, a posterior T3–4 laminectomy and intradural repair of the ventral dural defect were performed. The patient recovered with complete resolution of symptoms and no neurological deficits or weakness. Postoperative MRI showed resolution. LESSONS: Identifying a pathological defect can be challenging in SIH, especially in chronic cases that mimic Chiari malformation type I due to tonsillar decent. The authors illustrate the clinical, radiological, and surgical framework utilized at their institution for managing a chronic SIH case due to a ventral dural defect. https://thejns.org/doi/10.3171/CASE26369
- Open Access
- 16 April 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (8) , 2629-2642
Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension
Calcitonin gene-related peptide (CGRP) is a key mediator in migraine pathophysiology. Idiopathic intracranial hypertension (IIH) headache phenotype is now understood to be typically migraine-like, but it is unclear whether CGRP directly provokes IIH headaches or alters intracranial pressure (ICP) dynamics. We conducted a randomised, double-blind, placebo-controlled, two-way crossover trial to address this. Twenty women with IIH and no prior migraine were randomly assigned to receive a 20-min continuous intravenous infusion of CGRP (1.5 μg/min) or placebo (isotonic saline). The primary outcome was the difference in the proportion of participants who developed a provoked headache attack between CGRP and placebo during the 12 h observation after infusion. Secondary outcomes included the area under the curve (AUC) for headache intensity from -10 min to 12 h, the timing and duration of headache features, and baseline-adjusted changes for vital signs, cerebrovascular haemodynamics and ICP. Seventeen participants with mean (SD) age 26.7 (6.4) years completed both visits. Twelve (71%) participants developed a typical IIH headache attack with migraine-like features after CGRP compared with three (18%) after placebo (risk difference 53%; 95% CI, 26–79; P = 0.004). The AUC-10min-12h for headache intensity was higher after CGRP than after placebo (P = 0.016). The mean ICP remained unchanged, whereas ICP amplitude increased significantly after CGRP (P = 0.005). Vital signs and cerebrovascular haemodynamics AUC-10min-90min were significantly altered after CGRP (increased: heart rate (P < 0.001), tissue oxygenation index (P = 0.041), oxygenated haemoglobin (P < 0.001) and decreased: mean arterial pressure (P = 0.010), middle cerebral artery blood velocity (P = 0.006)). CGRP reliably provoked typical IIH headache attacks (which have migraine-like features) and increased ICP pulse amplitude, as a measure of intracranial compliance, without altering mean pressure. These findings provide mechanistic support for CGRP involvement in headache attributed to IIH and justify prospective evaluation of CGRP pathway blockade in this population.
- 16 April 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (8) , 2629-2642
Open AccessCalcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension
Calcitonin gene-related peptide (CGRP) is a key mediator in migraine pathophysiology. Idiopathic intracranial hypertension (IIH) headache phenotype is now understood to be typically migraine-like, but it is unclear whether CGRP directly provokes IIH headaches or alters intracranial pressure (ICP) dynamics. We conducted a randomised, double-blind, placebo-controlled, two-way crossover trial to address this. Twenty women with IIH and no prior migraine were randomly assigned to receive a 20-min continuous intravenous infusion of CGRP (1.5 μg/min) or placebo (isotonic saline). The primary outcome was the difference in the proportion of participants who developed a provoked headache attack between CGRP and placebo during the 12 h observation after infusion. Secondary outcomes included the area under the curve (AUC) for headache intensity from -10 min to 12 h, the timing and duration of headache features, and baseline-adjusted changes for vital signs, cerebrovascular haemodynamics and ICP. Seventeen participants with mean (SD) age 26.7 (6.4) years completed both visits. Twelve (71%) participants developed a typical IIH headache attack with migraine-like features after CGRP compared with three (18%) after placebo (risk difference 53%; 95% CI, 26–79; P = 0.004). The AUC-10min-12h for headache intensity was higher after CGRP than after placebo (P = 0.016). The mean ICP remained unchanged, whereas ICP amplitude increased significantly after CGRP (P = 0.005). Vital signs and cerebrovascular haemodynamics AUC-10min-90min were significantly altered after CGRP (increased: heart rate (P < 0.001), tissue oxygenation index (P = 0.041), oxygenated haemoglobin (P < 0.001) and decreased: mean arterial pressure (P = 0.010), middle cerebral artery blood velocity (P = 0.006)). CGRP reliably provoked typical IIH headache attacks (which have migraine-like features) and increased ICP pulse amplitude, as a measure of intracranial compliance, without altering mean pressure. These findings provide mechanistic support for CGRP involvement in headache attributed to IIH and justify prospective evaluation of CGRP pathway blockade in this population.
- Open Access
- 19 February 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (10) , 3614-3630
P2X7R-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics
Traumatic brain injury (TBI) is a major cause of death throughout the world and currently there are no approved drugs to treat this debilitating condition emphasising the clear unmet substantial clinical need. It is well recognised that microglial activation and the hostile neuroinflammatory response arising after the initial insult provides a therapeutic window for pharmacological intervention. The purinergic P2X7 receptor (P2X7R) is a key driver of neuroinflammation in a range of animal models of TBI. To generate translational evidence for the role of the P2X7R, we optimised two human inflammatory models; human cells (monocyte-derived microglia (hMDM)) in vitro and human brain tissue ex vivo, to test the impact of clinical-stage brain-penetrant P2X7R antagonists. Using lipopolysaccharide (LPS)-primed hMDM, the P2X7R agonist, BzATP, evoked a concentration-dependent increase in pro-inflammatory IL-1β and IL-18 release, which was antagonised in a concentration-dependent manner by selective P2X7R antagonists, and also inhibitors of either the NLRP3 complex or caspase-1, implicating a role for the inflammasome in P2X7R-mediated cytokine release. Using slices of human brain tissue, BzATP similarly evoked cytokine release in a concentration-dependent manner that was also antagonised by selective P2X7R antagonists at pharmacologically relevant concentrations. The present study demonstrates the ability of P2X7R antagonists to suppress the neuroinflammatory response from primed hMDM and human brain slices to offer direct translational data that central P2X7R antagonism may limit pathology-driven pro-inflammatory responses in the brain. This is predicted to improve the clinical outcomes for patients with TBI and other neuroinflammatory pathologies.
- 19 February 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (10) , 3614-3630
Open AccessP2X7R-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics
Traumatic brain injury (TBI) is a major cause of death throughout the world and currently there are no approved drugs to treat this debilitating condition emphasising the clear unmet substantial clinical need. It is well recognised that microglial activation and the hostile neuroinflammatory response arising after the initial insult provides a therapeutic window for pharmacological intervention. The purinergic P2X7 receptor (P2X7R) is a key driver of neuroinflammation in a range of animal models of TBI. To generate translational evidence for the role of the P2X7R, we optimised two human inflammatory models; human cells (monocyte-derived microglia (hMDM)) in vitro and human brain tissue ex vivo, to test the impact of clinical-stage brain-penetrant P2X7R antagonists. Using lipopolysaccharide (LPS)-primed hMDM, the P2X7R agonist, BzATP, evoked a concentration-dependent increase in pro-inflammatory IL-1β and IL-18 release, which was antagonised in a concentration-dependent manner by selective P2X7R antagonists, and also inhibitors of either the NLRP3 complex or caspase-1, implicating a role for the inflammasome in P2X7R-mediated cytokine release. Using slices of human brain tissue, BzATP similarly evoked cytokine release in a concentration-dependent manner that was also antagonised by selective P2X7R antagonists at pharmacologically relevant concentrations. The present study demonstrates the ability of P2X7R antagonists to suppress the neuroinflammatory response from primed hMDM and human brain slices to offer direct translational data that central P2X7R antagonism may limit pathology-driven pro-inflammatory responses in the brain. This is predicted to improve the clinical outcomes for patients with TBI and other neuroinflammatory pathologies.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , R49-R66
Management of endocrine disease: update on the management of pituitary apoplexy
Pituitary apoplexy (PA) is a rare but potentially life-threatening endocrine emergency caused by sudden hemorrhage or infarction usually within a pituitary tumor. Clinical presentation is highly variable, ranging from isolated headache to severe visual loss or altered consciousness. Prompt recognition, multidisciplinary evaluation, and timely management are essential to improve outcomes. Recent prospective and real-world studies have challenged the traditional view that urgent surgery is always required. Conservative management has been proposed to be a safe and effective option, although comparisons with the outcomes after surgical intervention are limited by differences in the severity of the clinical picture at presentation of the PA. Clinical decisions remain complex and must consider tumor size, symptom progression, radiological features, and individual comorbidities. The Pituitary Apoplexy Score helps guide management but has limitations, as it does not capture key variables such as persistent headache or evolving visual symptoms. Immediate management focuses on hemodynamic stabilization, stress-dose glucocorticoid administration, and neuro-ophthalmological monitoring. Surgical decompression should be considered in patients with progressive visual deterioration or altered consciousness. Follow-up must include hormonal reassessment, ophthalmological evaluation, and imaging surveillance. Although rare, recurrence of PA and tumor regrowth may occur, requiring long-term monitoring. This review provides an updated and pragmatic approach for the diagnosis, acute care, and long-term follow-up of PA, summarizing current evidence and highlighting ongoing controversies, including surgical timing and predictors of conservative treatment failure.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , R49-R66
Management of endocrine disease: update on the management of pituitary apoplexy
Pituitary apoplexy (PA) is a rare but potentially life-threatening endocrine emergency caused by sudden hemorrhage or infarction usually within a pituitary tumor. Clinical presentation is highly variable, ranging from isolated headache to severe visual loss or altered consciousness. Prompt recognition, multidisciplinary evaluation, and timely management are essential to improve outcomes. Recent prospective and real-world studies have challenged the traditional view that urgent surgery is always required. Conservative management has been proposed to be a safe and effective option, although comparisons with the outcomes after surgical intervention are limited by differences in the severity of the clinical picture at presentation of the PA. Clinical decisions remain complex and must consider tumor size, symptom progression, radiological features, and individual comorbidities. The Pituitary Apoplexy Score helps guide management but has limitations, as it does not capture key variables such as persistent headache or evolving visual symptoms. Immediate management focuses on hemodynamic stabilization, stress-dose glucocorticoid administration, and neuro-ophthalmological monitoring. Surgical decompression should be considered in patients with progressive visual deterioration or altered consciousness. Follow-up must include hormonal reassessment, ophthalmological evaluation, and imaging surveillance. Although rare, recurrence of PA and tumor regrowth may occur, requiring long-term monitoring. This review provides an updated and pragmatic approach for the diagnosis, acute care, and long-term follow-up of PA, summarizing current evidence and highlighting ongoing controversies, including surgical timing and predictors of conservative treatment failure.
- Open Access
- 4 October 2025
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 39 (5) , 102047
Ectopic craniopharyngiomas
- 4 October 2025
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 39 (5) , 102047
Open AccessEctopic craniopharyngiomas
- Open Access
- 2 October 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (10) , e70370
Treating Sight Threatening Papilloedema in Idiopathic Intracranial Hypertension: Temporary Versus Permanent Intervention
- 2 October 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (10) , e70370
Open AccessTreating Sight Threatening Papilloedema in Idiopathic Intracranial Hypertension: Temporary Versus Permanent Intervention
- Open Access
- 15 July 2025
- Published by Springer Nature in Eye
- p. 1-2
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial
- 15 July 2025
- Published by Springer Nature in Eye
- p. 1-2
Open AccessInfographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial
- Open Access
- 30 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , 680-690
Conservatively managed non-functioning pituitary macroadenomas—cohort study from the UK Non-functioning Pituitary Adenoma Consortium
Objective: Surveillance is often adopted for asymptomatic non-functioning pituitary macroadenomas (macroNFPAs). Due to low-quality evidence, uncertainty remains on optimal frequency of imaging/biochemical monitoring and indications for surgery. We assessed the natural history and outcomes of patients with macroNFPA who had monitoring as initial management choice from the UK NFPA Consortium. Design: This was a multicentre, retrospective, cohort study involving 21 UK endocrine departments. Methods: Clinical, imaging, and hormonal data of 949 patients followed up between January, 1, 2005 and March, 1, 2022 were analysed. Results: Incidence rate for tumour enlargement was 9.8 per 100 patient-years (95% CI, 8.8-10.8), with cumulative probabilities 1.6%, 8.1%, 18.4%, 29.2%, and 43.6% at 6-month, 1-year, 2-year, 3-year, and 5-year follow-up, respectively; rates were higher in tumours abutting/displacing optic chiasm than those not in contact with it. Amongst macroNFPAs not in contact with optic chiasm showing enlargement within 6 months, none impacted visual fields. In tumours with enlargement and continued monitoring (median 2.6 years), further growth occurred in 60.5% (33.8% probability at 2 years), stability in 35.5%, and shrinkage in 4.0%. Rates of new pituitary hormone deficits were 4.0%-4.9%, mainly driven by tumour enlargement. After transsphenoidal surgery, rates of hypopituitarism reversal were 12%-17% and those of additional anterior pituitary hormone deficits were 12%-15% (permanent vasopressin deficiency 3.5%). Conclusions: Our data provide evidence for monitoring protocols. MacroNFPAs not in contact with optic chiasm require less frequent imaging, and first follow-up scan can be delayed to 1 year. After first enlargement, variable tumour behaviour can occur. New hypopituitarism in stable tumours is rare, challenging necessity of regular pituitary function assessment.
- 30 April 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (5) , 680-690
Open AccessConservatively managed non-functioning pituitary macroadenomas—cohort study from the UK Non-functioning Pituitary Adenoma Consortium
Objective: Surveillance is often adopted for asymptomatic non-functioning pituitary macroadenomas (macroNFPAs). Due to low-quality evidence, uncertainty remains on optimal frequency of imaging/biochemical monitoring and indications for surgery. We assessed the natural history and outcomes of patients with macroNFPA who had monitoring as initial management choice from the UK NFPA Consortium. Design: This was a multicentre, retrospective, cohort study involving 21 UK endocrine departments. Methods: Clinical, imaging, and hormonal data of 949 patients followed up between January, 1, 2005 and March, 1, 2022 were analysed. Results: Incidence rate for tumour enlargement was 9.8 per 100 patient-years (95% CI, 8.8-10.8), with cumulative probabilities 1.6%, 8.1%, 18.4%, 29.2%, and 43.6% at 6-month, 1-year, 2-year, 3-year, and 5-year follow-up, respectively; rates were higher in tumours abutting/displacing optic chiasm than those not in contact with it. Amongst macroNFPAs not in contact with optic chiasm showing enlargement within 6 months, none impacted visual fields. In tumours with enlargement and continued monitoring (median 2.6 years), further growth occurred in 60.5% (33.8% probability at 2 years), stability in 35.5%, and shrinkage in 4.0%. Rates of new pituitary hormone deficits were 4.0%-4.9%, mainly driven by tumour enlargement. After transsphenoidal surgery, rates of hypopituitarism reversal were 12%-17% and those of additional anterior pituitary hormone deficits were 12%-15% (permanent vasopressin deficiency 3.5%). Conclusions: Our data provide evidence for monitoring protocols. MacroNFPAs not in contact with optic chiasm require less frequent imaging, and first follow-up scan can be delayed to 1 year. After first enlargement, variable tumour behaviour can occur. New hypopituitarism in stable tumours is rare, challenging necessity of regular pituitary function assessment.